RenovoRx to Present at the LD Micro Invitational XIII Conference
24 Maio 2023 - 9:30AM
Business Wire
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a
biopharmaceutical company focused on the localized treatment of
cancers, today announced that Shaun Bagai, CEO, will present at the
13th Annual LD Micro Invitational, held on June 6-8, 2023 at the
Luxe Sunset Boulevard Hotel in Los Angeles, California.
Mr. Bagai will provide a corporate update including recently
announced positive interim data for the Company’s ongoing open
label, randomized Phase III TIGeR-PaC clinical trial to treat
Locally Advanced Pancreatic Cancer (LAPC). Interim data
demonstrated that patients on the RenovoGem™ test arm demonstrated
a 60% survival benefit and 65% side effect reduction versus
systemic chemotherapy.
Presentation Details:
Date: Tuesday, June 6, 2023 Time: 1:00 p.m. – 1:25
p.m. PT Registration/Webcast Link:
https://ldinv13.sequireevents.com/
For more information about the conference, or to schedule a
one-on-one meeting with RenovoRx’s management team, please contact
your appropriate LD Micro representatives, or email
renovorx@kcsa.com.
A webcast of the event will be available for a limited time on
the Events page in the Investors section of the Company’s
website.
About RenovoGem
RenovoGem™ is the first drug-device combination product
candidate that utilizes the RenovoTAMP® therapy platform via
pressure-mediated delivery technology to deliver gemcitabine, an
FDA-approved systemic chemotherapy, locally across the arterial
wall to bathe tumor tissue in the chemotherapy. RenovoGem is
currently being evaluated in the Phase III TIGeR-PaC clinical trial
study in Locally Advanced Pancreatic Cancer (LAPC) patients. The
Company plans to investigate RenovoGem in extrahepatic
Cholangiocarcinoma (eCCA) in a clinical trial, which is anticipated
to begin in the first half of 2023. RenovoGem™ is currently under
investigation for the intra-arterial delivery of gemcitabine and
has not been approved for commercial sale.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company with a
vision to disrupt the current paradigm of cancer treatment. Our
mission is to lead a revolution in oncology therapy by delivering
its innovative and targeted intra-arterial (IA) delivery of
chemotherapy directly to solid tumors. The proprietary RenovoRx
Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform aims
to avoid the harsh side effects typical of the current standard of
care, or systemic delivery methods, thus improving patient
well-being and, potentially extension of life, so more time may be
enjoyed with loved ones. RenovoTAMP utilizes approved
chemotherapeutics with validated mechanisms of action and
well-established safety and clinical use, with the goal of
improving their safety, tolerance, and widening their therapeutic
window by providing more targeted delivery at the location of the
tumor tissue. RenovoRx’s lead product candidate, RenovoGem™, is a
combination of gemcitabine and its patented delivery system,
RenovoCath®, and is regulated by the FDA as a novel oncology drug
product to treat unresectable locally advanced pancreatic cancer
(LAPC). RenovoGem is currently being studied in the Phase III
TIGeR-PaC clinical trial for the treatment of LAPC.
RenovoRx’s patent portfolio for its therapy platform and product
candidates includes eight issued U.S. patents, one issued European
patent, and several additional patents pending in the US, EU and
Asia. RenovoRx has been granted Orphan Drug Designation for
intra-arterial delivery of gemcitabine for the treatment of both
pancreatic cancer and bile duct cancer (cholangiocarcinoma).
Learn more by visiting the RenovoRx website or following
RenovoRx on Facebook, LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230524005310/en/
Investor Contact: KCSA Strategic Communications Valter
Pinto or Jack Perkins T:212-896-1254 renovorx@kcsa.com
Media Contact: Kimberly Ha T: 9172915744
kimberly.ha@kkhadvisors.com
RenovoRx (NASDAQ:RNXT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
RenovoRx (NASDAQ:RNXT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024